TrialBMC ophthalmology2024

A phase III, multicentre, randomised, investigator-masked, cross-over, comparative, non-inferiority trial evaluating the efficacy and tolerability of generic preservative-free Latanoprost (Polpharma S.A.) compared to Xalatan

Norbert Czumbel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.